Discovery and in vitro characterization of the novel, tyrosine-based, non-thiazolidinedione PPARγ agonist GI262570

被引：0

作者：

Cobb, JE ^{[1
]}

Henke, BR ^{[1
]}

Blanchard, SG ^{[1
]}

机构：

[1] Glaxo Wellcome Inc, Res Triangle Pk, NC 27709 USA

来源：

DIABETOLOGIA | 2000年 / 43卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

725

引用

页码：A189 / A189

页数：1

共 17 条

[1] GI262570, a non-thiazolidinedione, tyrosine-based PPARγ agonist improves overall metabolic control in combination with glibenclamide
Raz, I
Kler, L
Edwards, R
McNeil, S
DIABETOLOGIA, 2000, 43 : A188 - A188
[2] Monotherapy with GI262570, a tyrosine-based non-thiazolidinedione PPARγ agonist, improves metabolic control in Type 2 diabetes mellitus patients
Fiedorek, FT
Wilson, GG
Frith, L
Patel, J
Abou-Donia, M
DIABETES, 2000, 49 : A38 - A39
[3] In vitro characterization of the novel, tyrosine-based PPARγ agonist GI262570.
Henke, BR
Blanchard, SG
DIABETES, 2000, 49 : A110 - A110
[4] The novel tyrosine-based PPARγ agonist GI262570 shows preferential binding to PPARγ complexed with RXRα and CBP
Blanchard, SG
Kliewer, SA
Parks, DJ
May, JM
DIABETES, 2000, 49 : A97 - A97
[5] Monotherapy with GI262570, a tyrosine-based non-thiazolidinedione PPARγ agonist, significantly reduces triglyceride and increases HDL-C concentrations in patients with Type 2 diabetes mellitus
Wilson, GG
Abou-Donia, M
Frith, L
Patel, J
Fiedorek, FT
DIABETES, 2000, 49 : A39 - A39
[6] Monotherapy with GI262570, a non-thiazolidinedione PPARγ agonist, reduces triglyceride and increases HDL-C in patients with type 2 diabetes
Fiedorek, FT
Wilson, GG
Abou-Donia, M
Frith, L
Patel, J
DIABETOLOGIA, 2000, 43 : A189 - A189
[7] GI262570, a non-thiazolidinedione PPARγ agonist, improves metabolic control in patients with type 2 diabetes mellitus when combined with glibenclamide treatment
Raz, I
Kler, L
Edwards, RC
McNeil, SJ
DIABETES, 2000, 49 : A129 - A129
[8] Monotherapy with GI262570, a non-thiazolidinedione PPARγ agonist, improves glycemic control in type 2 diabetes mellitus patients (T2DM)
Abou-Donia, M
Fiedorek, FT
Wilson, GG
Frith, L
Patel, J
DIABETOLOGIA, 2000, 43 : A189 - A189
[9] Anti-hypertensive effect of farglitazar, a tyrosine-based non-thiazolidinedione PPARγ agonist, in patients with type 2 diabetes and hypertension
Home, PD
Piaditis, G
Koelendorf, K
Raz, I
Murphy, L
Smith, PL
Kler, L
Dave, J
Tandy, D
DIABETES, 2001, 50 : A117 - A117
[10] GI262570, a tyrosine-based PPARγ agonist, reduces triglycerides and increases HDL-C concentrations in patients with type 2 diabetes mellitus when combined with glibenclamide treatment
Edwards, RC
Kler, L
McNeil, SJ
Round, P
DIABETES, 2000, 49 : A104 - A105

← 1 2 →